Treatment of patients with lower urinary tract symptoms in Moscow


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

Introduction. In recent years, there has been a persistent tendency to a decrease in surgical treatment of patients with lower urinary symptoms (LUTS). This fact can be explained by variety drugs which have acceptable safety and high efficiency for treatment of urinary disorders. As part of our survey of men in Moscow region, the trends in prescribing the different drugs for the LUTS was studied. In addition, the duration of therapy and patient adherence were analyzed. Materials and methods. A prospective multicenter epidemiological study “Characteristics of lower urinary tract symptoms in men in the Moscow region” was carried out using data obtained from April 1 to May 31, 2017 with anonymous survey of 525 men with mean age of 64.2±9.93 years, living in Moscow and went to the urologist with urinary disorders. All respondents answered questions from specially designed questionnaire consisted from 140 items. All medical data were analyzed, including received drugs, the duration of the therapy and subjective assessment of efficiency. Results. A total of 419 patients from 525 (79.8%) received any kind of therapy. The most commonly used drugs were а-blockers, which consisted 65% of all prescriptions. Other drugs were administered significantly rarely. It is surprisingly, that 85.6% of respondents in Moscow region received the original а-blockers, not generic drugs. Satisfaction rate was 74.3%. Most of patients (58.3%) had received а-blockers for 1-3 years and 33.3% administered these drugs for more than 3 years. Combined drug therapy was the second most popular (25.5%). The most commonly used combination included а-blockers and inhibitors of 5а-reductase. In 90.6% cases the appointment was made by urologist. Conclusion. Drug therapy is the most popular treatment in patients with LUTS. Our data suggest that а-blockers as monotherapy or in combination with inhibitors of 5а-reductase is the most often prescribed therapy. These results are in concordance with the main conclusions of international studies dedicated to this issue.

Texto integral

Acesso é fechado

Sobre autores

D. Pushkar

A.I. Evdokimov Moscow State University of Medicine and Dentistry

corresponding member of RAS, MD, professor, Head of the Department of Urology, Chief urologist of the Ministry of Health of Russia and Moscow

P. Rasner

A.I. Evdokimov Moscow State University of Medicine and Dentistry; Municipal clinical hospital named after S.I. Spasokukotskiy of the Moscow Healthcare Department

Email: dr.rasner@gmail.com
MD, professor at the Department of Urology; Head of the Department of Urology №4

D. Kotenko

A.I. Evdokimov Moscow State University of Medicine and Dentistry

Ph.D., Department of Urology

A. Gerasimov

A.I. Evdokimov Moscow State University of Medicine and Dentistry

Ph.D. in physical and mathematical sciences, professor, Head of the Department of Medical informatics and statistics

S. Shabalkin

A.I. Evdokimov Moscow State University of Medicine and Dentistry

Department of Urology

Bibliografia

  1. Nickel J.C., Downey J., Benard F. et al. The Canadian benign prostatic hyperplasia audit study (CanBas). Can. Urol. Assoc. J. 2008;2(4):367-373.
  2. Milsom I., Abrams P., Cardozo L., Roberts R.G., Thrnoff J.W., Wein A.J. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001;87:760.
  3. Hutchison A., Farmer R., Verhamme K., Berges R., Navarrete R.V., Reich O., de la Rosette JJMCH. The Efficacy of Drugs for the Treatment of LUTS/ BPH, A Study in 6 European Countries. Eur Urol 2007;51(Issue 1):207-216.
  4. Пушкарь Д.Ю., Раснер П.И., Котенко Д.В., Герасимов А.Н., Шабалкин С.А. Особенности симптомов нижних мочевыводящих путей у мужчин Московского региона. Результаты эпидемиологического исследования. Урология. 2018;3:20-28.
  5. Fourcade R.O., Lacoin F., Roupret M. et al. Outcomes and general health-related quality of life among patients medically treated in general daily practice for lower urinary tract symptoms due to benign prostatic hyperplasia. World J. Urol. 2012;30(3):419-426.
  6. Park J., Lee Y.J., Lee J.W. et al. Comparative analysis of benign prostatic hyperplasia management by urologists and nonurologists: a Korean nationwide health insurance database study. Korean J Urol. 2015;56(3):233-239.
  7. Cindolo L., Pirozzi L., Fanizza C., Romero M., Turbano A., Autorino R., De Nunzio C., Schips L. Drug adherence and clinical outcomes for patients under pharmacological therapy for lower urinary tract symptoms related to benign prostatic hyperplasia: population-based cohort study. Eur Urol. 2015;68:418-427.
  8. Гаджиева З.К., Казилов Ю.Б., Аляев Ю.К., Абоян И.А., Казилов Б.Р. Нарушения мочеиспускания. Все ли мы о них знаем? Урология. 2014;1:20-26.
  9. Helfand B.T., Evans R.M., McVary K.T. et al. Medical treatment of LUTS/ BPH: analysis of 8,7 million American men. J Urol. 2009;181(4):647.
  10. Шпиленя Е.С. Доброкачественная гиперплазия предстательной железы: современное видение проблемы. Эффективная фармакотерапия. 2018;2:42-45.
  11. Verhamme K.M.C., Dieleman J.P., Bleumink G.S., J van der Lei, Sturken-boom M.C.J.M. Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care: the TRIUMPH project. Eur Urol. 2002;42:323-328.
  12. Nichol M.B., Knight T.K., Wu J., Barron R., Penson D.F. Evaluating use patterns of and adherence to medications for benign prostatic hyperplasia. J Urol. 2009;181(22):14-21.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2019